The Science of HER2-low Breast Cancer and Implications for the Pathology Team
#BREASTPATH Destiny of HER2/neu in the era of HER2-low in 2024
Is HER2-low a distinct subtype of breast cancer?
Remaining questions surrounding HER2-low breast cancer – how low can you go?
Evolving and Emerging Trends in HER2 Classification and Reporting in Breast Cancer
The evolution of HER2-low-positive breast cancer as a clinical subtype
The genomic characterization of primary and metastatic HER2-low breast cancers
DESTINY-Breast15: T-DXd in patients with HR+HR- and HER2-low or HER2 IHC 0 metastatic breast cancer
Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis
HER2 IHC Interpretation Guide (Examples and Challenging Scenarios)
The evolution of HER2-low breast cancer from primary to recurrence
The comprehensive genomic characterization of HER2-low breast cancer
Advances in HER2-positive and HER2-low Breast Cancer
A New View of the Spectrum of HER2 Expression and Significance of HER2 Low in Breast Cancer
Latest Update on HER2-Low Breast Cancer and Implications for Clinical Practice
HER2 In Breast Cancer: Testing Guidelines and New Treatment Approaches
Dr Rimm on Unmet Needs in Distinguishing Between HER2-Low and HER2-Ultralow Breast Cancer
Questions remaining in the field of HER2-low breast cancer
Remaining questions on the management of HER2-low breast cancer
HER2-low expression in breast cancer
